These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38872157)

  • 1. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma.
    Fan W; Xing Y; Yan S; Liu W; Ning J; Tian F; Wang X; Zhan Y; Luo L; Cao M; Huang J; Cai L
    Cancer Cell Int; 2024 Jun; 24(1):208. PubMed ID: 38872157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling.
    Cui J; Song Y; Han X; Hu J; Chen Y; Chen X; Xu X; Xing Y; Lu H; Cai L
    Front Oncol; 2020; 10():542007. PubMed ID: 33123465
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.
    Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H
    Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7.
    Li K; Peng ZY; Wang R; Li X; Du N; Liu DP; Zhang J; Zhang YF; Ma L; Sun Y; Tang SC; Ren H; Yang YP; Sun X
    Mol Cancer; 2023 Jul; 22(1):103. PubMed ID: 37393311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of the Transcriptome-wide m6A Methylome in Lung Adenocarcinoma by MeRIP Sequencing.
    Mao W; Yu Q; Wang K; Ma Q; Zheng Y; Zhang G; Luo W; Wang N; Wang Y
    Front Oncol; 2022; 12():791332. PubMed ID: 35903698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3 exerts synergistic effects on m6A methylation and histone modification to regulate the function of VGF in lung adenocarcinoma.
    Shi K; Sa R; Dou L; Wu Y; Dong Z; Fu X; Yu H
    Clin Epigenetics; 2023 Sep; 15(1):153. PubMed ID: 37742030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m
    Xu Y; Lv D; Yan C; Su H; Zhang X; Shi Y; Ying K
    Cancer Cell Int; 2022 Jan; 22(1):11. PubMed ID: 34996469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTBP3 mediates TGF-β-induced EMT and metastasis of lung adenocarcinoma.
    Dong C; Wu K; Gu S; Wang W; Xie S; Zhou Y
    Cell Cycle; 2022 Jul; 21(13):1406-1421. PubMed ID: 35323096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of resistance mechanisms to EGFR-TKIs and establishment and validation of prognostic model.
    Yang Z; Li H; Dong T; Li G; Chen D; Li S; Wang Y; Pan Y; Lu T; Yang G; Zhang G; Cheng P; Wang X
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):13773-13792. PubMed ID: 37532906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner.
    Chen H; Yu Y; Yang M; Huang H; Ma S; Hu J; Xi Z; Guo H; Yao G; Yang L; Huang X; Zhang F; Tan G; Wu H; Zheng W; Li L
    Cell Biosci; 2022 Feb; 12(1):19. PubMed ID: 35197112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-β2-induced alterations of m6A methylation in hTERT RPE-1 cells.
    Li X; Zhao X; Yin R; Yuan M; Zhang Y; Li X
    Exp Eye Res; 2024 Apr; 241():109839. PubMed ID: 38395214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA demethylase ALKBH5 inhibits TGF-β-induced EMT by regulating TGF-β/SMAD signaling in non-small cell lung cancer.
    Sun Z; Su Z; Zhou Z; Wang S; Wang Z; Tong X; Li C; Wang Y; Chen X; Lei Z; Zhang HT
    FASEB J; 2022 May; 36(5):e22283. PubMed ID: 35344216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
    Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
    J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
    Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
    Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
    [No Abstract]   [Full Text] [Related]  

  • 17. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.
    Song H; Liu D; Wang L; Liu K; Chen C; Wang L; Ren Y; Ju B; Zhong F; Jiang X; Wang G; Chen ZS; Zou C
    Mol Cancer; 2022 Feb; 21(1):43. PubMed ID: 35144642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression.
    Zhang H; Wang SQ; Wang L; Lin H; Zhu JB; Chen R; Li LF; Cheng YD; Duan CJ; Zhang CF
    Cell Death Dis; 2022 Jul; 13(7):657. PubMed ID: 35902569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma.
    Bian S; Ni W; Zhu M; Song Q; Zhang J; Ni R; Zheng W
    Front Mol Biosci; 2020; 7():604766. PubMed ID: 33363211
    [No Abstract]   [Full Text] [Related]  

  • 20. YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition.
    Luo X; Cao M; Gao F; He X
    Exp Hematol Oncol; 2021 Jun; 10(1):35. PubMed ID: 34088349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.